^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    COL6A1 (Collagen Type VI Alpha 1 Chain)

    i
    Other names: COL6A1, Collagen Type VI Alpha 1 Chain, Collagen, Type VI, Alpha 1, Collagen Alpha-1(VI) Chain, Epididymis Secretory Sperm Binding Protein, Collagen VI, Alpha-1 Polypeptide, Alpha 1 (VI) Chain (61 AA), BTHLM1, UCHMD1, OPLL
    3d
    Single-Cell RNA Sequencing Reveals the Cellular and Molecular Differences Between Myxofibrosarcoma and Undifferentiated Pleomorphic Sarcoma. (PubMed, Med Sci (Basel))
    Differences were identified between UPS and MFS in the composition of lymphoid cell populations and in the intercellular interactions. This proposes deeper understanding of the biological differences between these sarcoma subtypes and may be important for the development of new therapeutic approaches, although further validation of the findings is required.
    Journal
    |
    CD8 (cluster of differentiation 8) • COL1A1 (Collagen Type I Alpha 1 Chain) • COL6A1 (Collagen Type VI Alpha 1 Chain) • CD80 (CD80 Molecule) • LAMC1 (Laminin Subunit Gamma 1)
    3ms
    Endothelial cells sense temozolomide resistance to facilitate monocyte-derived macrophage infiltration in glioblastoma. (PubMed, Drug Resist Updat)
    This study identifies a novel signaling cascade whereby TMZ-resistant GBM secretes COL6A1 to activate an IKZF1-UBD axis in ECs, disrupting blood vessel integrity and facilitating MDM infiltration. Our findings delineate the pivotal mechanism by which tumor cells engage ECs to drive MDM infiltration - a linchpin part of the positive-feedback loop that couples TMZ resistance to MDM influx. Targeting IKZF1 with LEN represents a promising strategy for restoring endothelial barrier function, reducing MDM infiltration, and enhancing chemosensitivity in GBM.
    Journal
    |
    IKZF1 (IKAROS Family Zinc Finger 1) • CHD1 (Chromodomain Helicase DNA Binding Protein 1) • COL6A1 (Collagen Type VI Alpha 1 Chain) • CLDN5 (Claudin 5) • ITGB1 (Integrin Subunit Beta 1)
    |
    lenalidomide • temozolomide
    3ms
    Synergistic Anticancer Effects of COL6A1 Downregulation and the PD1 Inhibitor Pembrolizumab in Bladder Cancer. (PubMed, J Biochem Mol Toxicol)
    Importantly, COL6A1 downregulation enhanced the therapeutic efficacy of pembrolizumab on bladder cancer cell malignant progression and immune escape. Combination of COL6A1 downregulation and pembrolizumab synergistically suppressed bladder cancer cell growth and metastasis, providing the possibility of inhibiting bladder cancer progression.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • COL6A1 (Collagen Type VI Alpha 1 Chain)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab)
    4ms
    The RNA N6-methyladenosine methylome coordinates long non-coding RNAs to mediate cancer drug resistance by activating PI3K signaling. (PubMed, Cell Death Dis)
    Treatment with PI3K inhibitor alpelisib eradicates resistant cells in vitro and in vivo, with prolonged survival of leukemic mice through downregulation of F2R, ITGA2, and COL6A1. Thus, the lncRNA-m6A-PI3K cascade represents a new non-genetic predictor for drug resistance and poorer prognosis in cancer, and a pan-cancer mechanism underlying TKI resistance.
    Journal
    |
    COL6A1 (Collagen Type VI Alpha 1 Chain) • FTO (Alpha-Ketoglutarate-Dependent Dioxygenase FTO) • ITGA2 (Integrin Subunit Alpha 2)
    |
    Piqray (alpelisib)
    4ms
    Integrative Bulk and Single-Cell Transcriptomic Profiling Reveals Oxidative Stress-Related Genes and Potential Therapeutic Targets in Osteoarthritis. (PubMed, Mediators Inflamm)
    Furthermore, molecular docking and dynamics simulations identified ursolic acid (UA) as a stable small-molecule FOS binder, and in vitro experiments confirmed its inhibitory effects on oxidative stress and inflammation, comparable to FOS silencing or pharmacological inhibition. Collectively, our findings suggest that oxidative stress-related genes, particularly FOS, play a central role in OA pathogenesis by linking redox imbalance to immune dysregulation and chondrocyte injury, and highlight UA as a potential therapeutic candidate for OA management.
    Journal
    |
    TP53 (Tumor protein P53) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • COL6A1 (Collagen Type VI Alpha 1 Chain) • IL1B (Interleukin 1, beta) • STC2 (Stanniocalcin 2) • HSPA8 (Heat Shock Protein Family A (Hsp70) Member 8)
    4ms
    TGF-βI/FERMT2/COL6A1 Reciprocal Loop Drives Tumor-Stroma Crosstalk and Promotes Peritoneal Metastasis in Gastric Cancer. (PubMed, Int J Biol Sci)
    Together, these interactions constitute a TGF-β1/FERMT2/COL6A1 positive feedback loop that fuels tumor-stroma crosstalk and promotes peritoneal dissemination in GC. This study identifies a reciprocal regulatory loop involving FERMT2, TGF-β1, and COL6A1, which promotes tumor-stroma interaction and peritoneal dissemination, suggesting a potential therapeutic target for advanced gastric cancer.
    Journal
    |
    TGFB1 (Transforming Growth Factor Beta 1) • COL6A1 (Collagen Type VI Alpha 1 Chain) • ZEB2 (Zinc Finger E-Box Binding Homeobox 2)
    6ms
    Collagen proteins, thrombospondin 1 and lumican are differentially expressed across breast cancer subtypes by functional proteomics from core needle biopsy samples of Taiwanese breast cancer. (PubMed, Biochem Biophys Rep)
    Disease-specific survival discrepancy was observed comparing breast cancer patients of the upper and lower quartile of the collagen family (COL2A1, COL11A1, COL6A1, COL6A2), THBS1 and LUM gene expression signature (log-rank test, P = 0.06). Functional proteomics suggested that collagen proteins, thrombospondin 1 and lumican are differentially expressed across breast cancer subtypes.
    Journal • BRCA Biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • BRCA (Breast cancer early onset) • THBS1 (Thrombospondin 1) • COL1A1 (Collagen Type I Alpha 1 Chain) • COL6A1 (Collagen Type VI Alpha 1 Chain) • COL11A1 (Collagen Type XI Alpha 1 Chain) • COL2A1 (Collagen Type II Alpha 1 Chain) • COL6A2 (Collagen Type VI Alpha 2 Chain) • LUM (Lumican)
    6ms
    Extracellular Matrix and Fibroblast Activation in Lymphangioleiomyomatosis. (PubMed, Am J Respir Cell Mol Biol)
    This demonstrates that mTORC1-driven 4E-BP1/eIF4E rapamycin-insensitive translational control overrides transcriptional control of ECM genes. Inhibition by RMC-5552 of ECM and fibroblast activation may result in destruction of CSC-like LAM cells and provide more enduring therapy for LAM patients.
    Journal
    |
    EIF4EBP1 (Eukaryotic translation initiation factor 4E binding protein 1) • TGFB1 (Transforming Growth Factor Beta 1) • COL1A1 (Collagen Type I Alpha 1 Chain) • COL6A1 (Collagen Type VI Alpha 1 Chain)
    |
    RMC-5552
    7ms
    CXCL16 Producing Tumor Clones Are Shaping Immunosuppressive Microenvironment in Squamous Cell Carcinoma via CXCR6 Regulatory T Cell. (PubMed, Cancer Med)
    We suggest COL6A1 and ITGA5 promote the invasive and metastatic property of SCC. We also uncovered how SCC recruits Tregs via the CXCL16/CXCR6 axis to create a TME favorable for its survival. These molecules can be used as potential therapeutic targets for treatment of SCC.
    Journal
    |
    COL6A1 (Collagen Type VI Alpha 1 Chain) • CXCR6 (C-X-C Motif Chemokine Receptor 6) • CXCL16 (C-X-C Motif Chemokine Ligand 16) • ITGA5 (Integrin Subunit Alpha 5)
    7ms
    Noninvasive and Sensitive Biosensor for the Detection of Oral Cancer Prognostic Biomarkers. (PubMed, Small)
    Notably, the AdaBoost model, integrating the combined detection of biomarkers, achieves a 76% accuracy rate in identifying metastatic saliva samples. This non-invasive biosensor technology, combined with bioinformatics, presents a sensitive and reliable approach to improve clinical assessments and guiding therapeutic decisions for OSCC patients.
    Journal
    |
    COL6A1 (Collagen Type VI Alpha 1 Chain)
    8ms
    Fusion of spatiotemporal and network models to prioritize multiscale effects in single-cell perturbations. (PubMed, Brief Bioinform)
    In colitis, Perturb-STNet identified key genes (Csf1r, Col6a1, Lgr4, Myc, and Fzd5) and mediator pairs (Itga5-Flnc, Cd68-Csf1r, Csf1r-Cx3cl1, and Tnfrsf1b-Bmp1) involved in immune regulation, matrix remodeling, and epithelial repair, offering potential therapeutic targets. Overall, Perturb-STNet enables robust identification of spatiotemporal regulatory networks in single-cell perturbation data across diverse disease contexts.
    Journal
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase) • CD8 (cluster of differentiation 8) • CD79B (CD79b Molecule) • IL2RA (Interleukin 2 receptor, alpha) • CD5 (CD5 Molecule) • CD68 (CD68 Molecule) • CSF1R (Colony stimulating factor 1 receptor) • FOXP3 (Forkhead Box P3) • COL6A1 (Collagen Type VI Alpha 1 Chain) • CX3CL1 (C-X3-C Motif Chemokine Ligand 1) • KLRG1 (Killer Cell Lectin Like Receptor G1) • FLNC (Filamin C) • FZD5 (Frizzled Class Receptor 5) • ITGA5 (Integrin Subunit Alpha 5) • LGR4 (Leucine Rich Repeat Containing G Protein-Coupled Receptor 4) • TNFRSF1B (TNF Receptor Superfamily Member 1B)
    9ms
    Acquired resistance to immunotherapy by physical barriers with cancer cell-expressing collagens in non-small cell lung cancer. (PubMed, Proc Natl Acad Sci U S A)
    COL3A1 formed a castle-like barrier for a cluster of tumor cells and prevented T cell infiltration, while COL6A1 formed an armor-like barrier surrounding individual tumor cells to protect them against direct T cell attack. Our data reveal a tumor cell-intrinsic mechanism of AIR, mediated by collagen-containing physical barriers, which immediately suggests a clinical treatment option.
    Preclinical • Journal • IO biomarker
    |
    TGFB1 (Transforming Growth Factor Beta 1) • COL3A1 (Collagen Type III Alpha 1 Chain) • COL6A1 (Collagen Type VI Alpha 1 Chain)